Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 7 of 7 for “"dose individualization"”.

  1. Συγκριτική μελέτη σχημάτων κλασματοποίησης της ακτινοθεραπείας στον καρκίνο της ουροδόχου κύστης

    … within 19 days). Patients received a daily dose of 0/500/750/1000mg of amifostine using a dose-individualization algorithm (15.8%, 8.5%, 19.5% and 56.1% of patients respectively). Liposomal doxorubicin (Caelyx®) 20mg/m2 every two weeks was administered in 41/82 patients, for a total of 3-6 …

    greece Repository record for Συγκριτική μελέτη σχημάτων κλασματοποίησης της ακτινοθεραπείας στον καρκίνο της ουροδόχου κύστης (opens in a new tab)

  2. Advancing Personalized Medicine in Immunosuppression: Applications of Pharmacokinetics, Pharmacogenomics, and Pharmacomicrobiome

    … the microbiome may improve exposure prediction, dose individualization, and transplantation outcomes. They also highlight importance of combining pharmacokinetic modeling with multi-omics data to advance precision immunosuppressive therapy in transplantation settings.

    umn Repository record for Advancing Personalized Medicine in Immunosuppression: Applications of Pharmacokinetics, Pharmacogenomics, and Pharmacomicrobiome (opens in a new tab)

  3. Εξατομίκευση της εφαρμογής του tacrolimus σε ασθενείς με μεταμόσχευση νεφρού: φαρμακοκινητική και φαρμακογενετική προσέγγιση

    … was associated with significant lower tacrolimus dose adjusted concentration. Carriers of CYP3A5*1 allele had lower predicted measures for tacrolimus dose adjusted concentration and higher predicted measures for volume of distribution. Timepoint, in contrast with gender, had a statistically …

    greece Repository record for Εξατομίκευση της εφαρμογής του tacrolimus σε ασθενείς με μεταμόσχευση νεφρού: φαρμακοκινητική και φαρμακογενετική προσέγγιση (opens in a new tab)

  4. Clinical application of the Web-Accessible Population Pharmacokinetic Service – Hemophilia (WAPPS-Hemo): proposal for a pilot study of a population pharmacokinetic approach to tailored prophylaxis in hemophilia.

    … the 12 months’ follow-up. Conclusion The goal of dose individualization for clotting factor concentrates is to improve the outcomes in severe hemophilia patients. The PopPK approach has this potential, but whether the use of PopPK will be will translate into clinically or economically meaningful …

    mcmaster Repository record for Clinical application of the Web-Accessible Population Pharmacokinetic Service – Hemophilia (WAPPS-Hemo): proposal for a pilot study of a population pharmacokinetic approach to tailored prophylaxis in hemophilia. (opens in a new tab)

  5. Individualization of drug therapy considering pharmacokinetic and clinical factors

    … the rational use of drugs1, which includes the individualization of drug therapy. Clinical pharmacists therefore need a profound knowledge of the pharmacokinetic properties of relevant drugs, and clinical factors that are influencing these properties. Against the background of individualizing …

    wurz-thes Repository record for Individualization of drug therapy considering pharmacokinetic and clinical factors (opens in a new tab)

  6. Pharmacokinetic modelling of clinically relevant situations in the treatment of hemophilia A and B

    … be improved by incorporating knowledge of prior doses, and by conducting the PK study when samples are likely to still be quantifiable. Model performance is also dependent on the patient’s endogenous factor production, or baseline. In severe hemophilia patients, baseline factor activity may range …

    waterloo Repository record for Pharmacokinetic modelling of clinically relevant situations in the treatment of hemophilia A and B (opens in a new tab)

  7. Development of liquid chromatography methods for the quantification of kinase inhibitors and letermovir in human serum for the application during therapeutic drug monitoring in haemato-oncological patients

    … 6.22-15.9 ng/mL, dosage: 2 mg once daily). Dose adjustments because of undesirable side effects in clinical routine were common. The observed data do not support a general monitoring of dabrafenib and trametinib in clinical routine. However, they provide the evidence for associations between …

    wurz-thes Repository record for Development of liquid chromatography methods for the quantification of kinase inhibitors and letermovir in human serum for the application during therapeutic drug monitoring in haemato-oncological patients (opens in a new tab)